(Q84840768)

English

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

scientific article published on 01 November 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

tetanus vaccine

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

M Knuf

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

D Kieninger-Baum

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

P Habermehl

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

P Muttonen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

H Maurer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J Poolman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

D Boutriau

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

744-753

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Meningococcal conjugate vaccines: efficacy and new combinations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Invasive meningococcal disease in adolescents and young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Manson Lecture. Meningococcal meningitis in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Development of vaccines against meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Serogroup W-135 meningococcal disease during the Hajj, 2000

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Meningococcal surrogates of protection--serum bactericidal antibody activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Impact of meningococcal C conjugate vaccine use in Australia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.064

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.10.064

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19887137%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84840768&oldid=1562884691"